FT516 in Subjects With Advanced Hematologic Malignancies

General Information

Summary This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-sepcific cohorts.
Clinical trials phase Phase 1
Start date (estimated) 2019-10-04
End date (estimated) 2023-10-23
Clinical feature
Label acute myeloid leukemia
Link http://purl.obolibrary.org/obo/DOID_9119
Description A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.; OMIM mapping confirmed by DO. [SN].

Administrative Information

NCT number NCT04023071
ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04023071
Other study identifiers
Name FT516-101
Source weblink https://clinicaltrials.gov/ct2/show/NCT04023071
Public contact
Email clinical@fatetherapeutics.com
Public email clinical@fatetherapeutics.com
First name Rebecca
Last name Reynolds
Phone +1 (0)858-875-1800
Country
United States
Sponsors Fate Therapeutics

Cells

Which differentiated cell type is used
Label natural killer cell
Link http://purl.obolibrary.org/obo/CL_0000623
Description A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.

Recruitment

Recruitment Status Terminated
Estimated number of participants 72